GT Biopharma Inc. Common Stock (GTBP) Stock Price

GTBPStock

$0.30−72.45%52W

Market Cap$13.52M

P/E—

PEG Ratio1.05

Div yield—

Beta0.85

GTBP Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-48.63%

Price vs S&P 500 (4W)-6.49%

PEG Ratio1.05

VGM Score26.54

Book Value / Share (Quarterly)$0.22

P/TBV (Annual)52.56x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-0.37

Price vs S&P 500 (YTD)-73.01%

Gross Margin (TTM)36.51%

Net Profit Margin (TTM)-26209.52%

EPS (TTM)$-10.65

10-Day Avg Trading Volume0.46M

EPS Excl Extra (TTM)$-10.65

EPS (Annual)$-6.94

Dividend / Share (Annual)$0.02

ROI (Annual)-101.62%

Gross Margin (Annual)100.00%

Net Profit Margin (5Y Avg)-26774.13%

Cash / Share (Quarterly)$0.25

ROA (Last FY)-311.01%

EBITD / Share (TTM)$-1.07

ROE (5Y Avg)-569.56%

Operating Margin (TTM)-8623.81%

Cash Flow / Share (Annual)$-0.51

P/B Ratio1.74x

P/B Ratio (Quarterly)1.70x

Net Income / Employee (Annual)$-13,162,000

EV / Revenue (TTM)67.67x

Net Interest Coverage (TTM)-80.82x

ROA (TTM)-646.21%

EPS Incl Extra (Annual)$-6.94

Current Ratio (Annual)3.50x

Quick Ratio (Quarterly)3.97x

3-Month Avg Trading Volume1.20M

52-Week Price Return-72.45%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$0.24

P/S Ratio (Annual)488.38x

Asset Turnover (Annual)0.50x

52-Week High$1.37

Operating Margin (5Y Avg)-10668.30%

EPS Excl Extra (Annual)$-6.94

26-Week Price Return-37.39%

Quick Ratio (Annual)3.25x

13-Week Price Return-29.38%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)4.14x

Enterprise Value$4.26M

Asset Turnover (TTM)0.08x

Book Value / Share Growth (5Y)-84.55%

Revenue / Employee (Annual)$0

Inventory Turnover (Annual)2.71x

Pretax Margin (Annual)-79485.19%

Cash / Share (Annual)$0.27

3-Month Return Std Dev87.35%

Gross Margin (5Y Avg)26.61%

Net Income / Employee (TTM)$-47,734,000

ROE (Last FY)-101.62%

Net Interest Coverage (Annual)-208.37x

EPS Basic Excl Extra (Annual)$-6.94

P/FCF (TTM)1198.75x

Receivables Turnover (TTM)3.05x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-10.65

Receivables Turnover (Annual)3.05x

ROI (TTM)-321.96%

P/S Ratio (TTM)209.31x

Pretax Margin (5Y Avg)-26782.80%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$0.36

Price vs S&P 500 (52W)-90.76%

Year-to-Date Return-61.05%

5-Day Price Return11.04%

EPS Normalized (Annual)$-6.94

ROA (5Y Avg)-233.96%

Net Profit Margin (Annual)-79485.19%

Month-to-Date Return4.19%

Cash Flow / Share (TTM)$-0.27

EBITD / Share (Annual)$-7.57

Operating Margin (Annual)-33062.96%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-352.25%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-10.65

P/TBV (Quarterly)52.56x

P/B Ratio (Annual)1.44x

Inventory Turnover (TTM)2.71x

Pretax Margin (TTM)-26238.10%

Book Value / Share (Annual)$0.23

Price vs S&P 500 (13W)-32.17%

Beta0.85x

P/FCF (Annual)38.56x

Revenue / Share (TTM)$0.00

ROE (TTM)-321.96%

52-Week Low$0.26

vGradeD

mGradeD

vgmGradeD

GTBP Earnings Surprise History

Q2 25-0.55est. -0.68

Q3 25-0.83est. -0.38

Q4 25-4.84est. -0.22

Q1 26-0.11est. -0.08

Q2 26-0.12est. -0.08

GTBP Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.14

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
GTBPGT Biopharma Inc. Common Stock	D	—	D	$0.30
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About GT Biopharma Inc. Common Stock

GT Biopharma is a clinical-stage biopharmaceutical company developing immuno-oncology drugs using its proprietary TriKE platform. The platform's therapeutic candidates are designed to treat hematologic malignancies, sarcoma, and solid tumors. The company is advancing these novel therapies toward commercialization in the U.S.